AIM:DXRX

Stock Analysis Report

Executive Summary

Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide.

Snowflake

Fundamentals

Mediocre balance sheet with concerning outlook.

Share Price & News

How has Diaceutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.3%

DXRX

-1.7%

GB Life Sciences

0.08%

GB Market


1 Year Return

n/a

DXRX

2.7%

GB Life Sciences

3.5%

GB Market

Return vs Industry: Insufficient data to determine how DXRX performed against the UK Life Sciences industry.

Return vs Market: Insufficient data to determine how DXRX performed against the UK Market.


Shareholder returns

DXRXIndustryMarket
7 Day5.3%-1.7%0.08%
30 Day0.5%-7.9%-1.3%
90 Day8.8%-9.7%-2.2%
1 Yearn/a3.1%2.7%9.0%3.5%
3 Yearn/a21.0%19.9%18.1%3.1%
5 Yearn/a25.5%24.0%36.2%5.3%

Price Volatility Vs. Market

How volatile is Diaceutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Diaceutics undervalued compared to its fair value and its price relative to the market?

3.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DXRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DXRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DXRX is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: DXRX is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DXRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DXRX is overvalued based on its PB Ratio (3.8x) compared to the GB Life Sciences industry average (2.8x).


Next Steps

Future Growth

How is Diaceutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

150.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DXRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DXRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DXRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DXRX's revenue (18% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: DXRX's revenue (18% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DXRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Diaceutics performed over the past 5 years?

-2.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: DXRX is unprofitable, and losses have increased over the past 5 years at a rate of -2% per year.

Accelerating Growth: Unable to compare DXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DXRX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (14%).


Return on Equity

High ROE: DXRX has a negative Return on Equity (-0.83%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: DXRX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: DXRX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Diaceutics's financial position?


Financial Position Analysis

Short Term Liabilities: DXRX's short term assets (£17.3M) exceeds its short term liabilities (£1.7M)

Long Term Liabilities: DXRX's short term assets (17.3M) exceeds its long term liabilities (102.5K)


Debt to Equity History and Analysis

Debt Level: DXRX's debt to equity ratio (0.6%) is considered satisfactory

Reducing Debt: Insufficient data to determine if DXRX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: DXRX's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: DXRX is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet

Inventory Level: DXRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: DXRX's debt is covered by short term assets (assets are 169.162650x debt).


Next Steps

Dividend

What is Diaceutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate DXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DXRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DXRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DXRX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Diaceutics's salary, the management and board of directors tenure and is there insider trading?

0.3yrs

Average management tenure


CEO

Peter Keeling 0

0yrs

Tenure

0

Mr. Peter Keeling serves as Chief Executive Officer and Director of Diaceutics PLC. Mr. Keeling was Co-founder and Chief Executive at Diagnology Limited. 


Management Age and Tenure

0.3yrs

Average Tenure

Experienced Management: DXRX's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Peter Keeling

    CEO & Director

    • Tenure: 0yrs
  • Damian Thornton

    Chief Operating Officer

    • Tenure: 0yrs
  • Ryan Keeling

    Chief Innovation Officer & Director

    • Tenure: 0yrs
  • Jordan Clark

    Chief Technical Officer

    • Tenure: 0yrs
  • Philip White

    CFO, Company Secretary & Director

    • Tenure: 0yrs
  • Sarah Bondi

    Senior Director of Human Resources

    • Tenure: 0yrs
  • Zarina Bibi

    General Counsel

    • Tenure: 0.4yrs
  • Susanne Munksted

    Managing Director

    • Tenure: 0.8yrs
  • Derek Hosty

    Head of Global Data

    • Tenure: 0.2yrs
  • Amit Jain

    Managing Director

    • Tenure: 0.2yrs

Board Members

  • Julie Wallin

    Chairwoman

    • Tenure: 0yrs
  • Mike Wort (68yo)

    Non-Executive Director

    • Tenure: 0yrs
  • Peter Keeling

    CEO & Director

    • Tenure: 0yrs
  • Ryan Keeling

    Chief Innovation Officer & Director

    • Tenure: 0yrs
  • Philip White

    CFO, Company Secretary & Director

    • Tenure: 0yrs

Company Information

Diaceutics PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diaceutics PLC
  • Ticker: DXRX
  • Exchange: AIM
  • Founded:
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£68.887m
  • Shares outstanding: 69.58m
  • Website: https://www.diaceutics.com

Number of Employees


Location

  • Diaceutics PLC
  • Titanic Suites
  • Enterprise House
  • Belfast
  • County Antrim
  • BT2 8FE
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
7DCDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2019
DXRXAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2019

Biography

Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulati ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 22:08
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.